129 related articles for article (PubMed ID: 38314662)
21. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Mizuta S; Ugai T; Kato H; Doki N; Ota S; Kawakita T; Katayama Y; Kurokawa M; Nakamae H; Yano S; Nawa Y; Kanda Y; Fukuda T; Atsuta Y; Kako S
Int J Hematol; 2022 Sep; 116(3):393-400. PubMed ID: 35536509
[TBL] [Abstract][Full Text] [Related]
22. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Fujisawa S; Mizuta S; Akiyama H; Ueda Y; Aoyama Y; Hatta Y; Kakihana K; Dobashi N; Sugiura I; Onishi Y; Maeda T; Imai K; Ohtake S; Miyazaki Y; Ohnishi K; Matsuo K; Naoe T
Am J Hematol; 2017 Apr; 92(4):367-374. PubMed ID: 28103625
[TBL] [Abstract][Full Text] [Related]
24. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
Greil C; Engelhardt M; Ihorst G; Duque-Afonso J; Shoumariyeh K; Bertz H; Marks R; Zeiser R; Duyster J; Finke J; Wäsch R
Bone Marrow Transplant; 2021 Apr; 56(4):841-852. PubMed ID: 33130821
[TBL] [Abstract][Full Text] [Related]
26. Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.
Nishiwaki S; Terakura S; Yasuda T; Imahashi N; Sao H; Iida H; Kamiya Y; Niimi K; Morishita Y; Kohno A; Yokozawa T; Ohashi H; Sawa M; Kodera Y; Miyamura K
Int J Hematol; 2010 Apr; 91(3):419-25. PubMed ID: 20146028
[TBL] [Abstract][Full Text] [Related]
27. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
28. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
[TBL] [Abstract][Full Text] [Related]
31. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
Roos-Weil D; Dietrich S; Boumendil A; Polge E; Bron D; Carreras E; Iriondo Atienza A; Arcese W; Beelen DW; Cornelissen JJ; Kröger N; Milone G; Rossi G; Jardin F; Peters C; Rocha V; Sureda A; Mohty M; Dreger P;
Blood; 2013 Jan; 121(3):440-6. PubMed ID: 23203822
[TBL] [Abstract][Full Text] [Related]
32. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
Varda-Bloom N; Danylesko I; Shouval R; Eldror S; Lev A; Davidson J; Rosenthal E; Volchek Y; Shem-Tov N; Yerushalmi R; Shimoni A; Somech R; Nagler A
Oncotarget; 2017 Jan; 8(1):418-429. PubMed ID: 27880933
[TBL] [Abstract][Full Text] [Related]
33. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
[TBL] [Abstract][Full Text] [Related]
34. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
35. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
37. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.
Crotta A; Zhang J; Keir C
Curr Med Res Opin; 2018 Mar; 34(3):435-440. PubMed ID: 28945102
[TBL] [Abstract][Full Text] [Related]
38. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.
Hallböök H; Hägglund H; Stockelberg D; Nilsson PG; Karlsson K; Björkholm M; Linderholm M; Wahlin A; Linder O; Smedmyr B;
Bone Marrow Transplant; 2005 Jun; 35(12):1141-8. PubMed ID: 15834433
[TBL] [Abstract][Full Text] [Related]
39. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1.
Lv M; Jiang Q; Zhou DB; Hu Y; Liu DH; Wu DP; Wang JB; Jiang H; Wang J; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2020 May; 13(1):52. PubMed ID: 32414392
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
